1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell Penetrating Peptide Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell Penetrating Peptide Market Revenue and Volume, by Type
8.1.1 Protein-based CPPs (TAT peptide, Penetratin, Antp)
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Peptide-based CPPs (Oligoarginine peptide, Polysrginine peptide, Transportan)
8.1.2.1. Market Revenue and Volume Forecast
9.1. Cell Penetrating Peptide Market Revenue and Volume, by Application
9.1.1. Drug Delivery
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Gene Delivery
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Diagnostics
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Molecular Imaging
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Others (Vaccine development, Antimicrobial Therapy)
9.1.5.1. Market Revenue and Volume Forecast
10.1. Cell Penetrating Peptide Market Revenue and Volume, by End User
10.1.1. Pharmaceutical and Biotechnology Company
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Contract Research Organization (CROs)
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Hospitals and Clinics
10.1.3.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type
11.1.2. Market Revenue and Volume Forecast, by Application
11.1.3. Market Revenue and Volume Forecast, by End User
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type
11.1.4.2. Market Revenue and Volume Forecast, by Application
11.1.4.3. Market Revenue and Volume Forecast, by End User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type
11.1.5.2. Market Revenue and Volume Forecast, by Application
11.1.5.3. Market Revenue and Volume Forecast, by End User
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type
11.2.2. Market Revenue and Volume Forecast, by Application
11.2.3. Market Revenue and Volume Forecast, by End User
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type
11.2.4.2. Market Revenue and Volume Forecast, by Application
11.2.4.3. Market Revenue and Volume Forecast, by End User
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type
11.2.5.2. Market Revenue and Volume Forecast, by Application
11.2.5.3. Market Revenue and Volume Forecast, by End User
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type
11.2.6.2. Market Revenue and Volume Forecast, by Application
11.2.6.3. Market Revenue and Volume Forecast, by End User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type
11.2.7.2. Market Revenue and Volume Forecast, by Application
11.2.7.3. Market Revenue and Volume Forecast, by End User
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type
11.3.2. Market Revenue and Volume Forecast, by Application
11.3.3. Market Revenue and Volume Forecast, by End User
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type
11.3.4.2. Market Revenue and Volume Forecast, by Application
11.3.4.3. Market Revenue and Volume Forecast, by End User
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type
11.3.5.2. Market Revenue and Volume Forecast, by Application
11.3.5.3. Market Revenue and Volume Forecast, by End User
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type
11.3.6.2. Market Revenue and Volume Forecast, by Application
11.3.6.3. Market Revenue and Volume Forecast, by End User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type
11.3.7.2. Market Revenue and Volume Forecast, by Application
11.3.7.3. Market Revenue and Volume Forecast, by End User
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type
11.4.2. Market Revenue and Volume Forecast, by Application
11.4.3. Market Revenue and Volume Forecast, by End User
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type
11.4.4.2. Market Revenue and Volume Forecast, by Application
11.4.4.3. Market Revenue and Volume Forecast, by End User
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type
11.4.5.2. Market Revenue and Volume Forecast, by Application
11.4.5.3. Market Revenue and Volume Forecast, by End User
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type
11.4.6.2. Market Revenue and Volume Forecast, by Application
11.4.6.3. Market Revenue and Volume Forecast, by End User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type
11.4.7.2. Market Revenue and Volume Forecast, by Application
11.4.7.3. Market Revenue and Volume Forecast, by End User
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type
11.5.2. Market Revenue and Volume Forecast, by Application
11.5.3. Market Revenue and Volume Forecast, by End User
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type
11.5.4.2. Market Revenue and Volume Forecast, by Application
11.5.4.3. Market Revenue and Volume Forecast, by End User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type
11.5.5.2. Market Revenue and Volume Forecast, by Application
11.5.5.3. Market Revenue and Volume Forecast, by End User
12.1. Bachem Holding AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bio-Synthesis Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. PolyPeptide Laboratories AB
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Tocris Bioscience
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Avidity Biosciences
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. R&D Systems
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novo Nordisk A/S
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. CordenPharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Creative Peptides
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. PEPperPRINT GmbH
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
